Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition.
Toshio SuzukiYuji TadaSanthi GladsonRintaro NishimuraIwao ShimomuraSatoshi KarasawaKoichiro TatsumiJames WestPublished in: Respiratory research (2017)
Inhibiting DPP-4 signaling by vildagliptin could ameliorate pulmonary fibrosis by downregulating EndMT in systemic LPS-induced lung injury.